Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.
The diversification away from Xtandi has only just begun.
Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.
An Acceleron update in December could reignite investor interest in the stock.
The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.
Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.
Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes.